Long-Term Plavix Use May Increase Risks for Stent Patients

No Longer Accepting Cases

November 17, 2014 — Stent patients who use Plavix plus aspirin for more than 30 months may face an increased risk of death and bleeding, but a 71% lower risk of blood clots and a 29% lower risk of heart attack and stroke, according to a new study.

Anti-platelet drugs, such as Plavix (clopidogrel) and Effient (prasugrel) are used to prevent blood clots. They are often prescribed in combination with aspirin in patients who have had a coronary stent implanted after a heart attack.

Stents are metal-mesh tubes that prop open narrow arteries that supply blood to the heart muscle. Drug-eluting stents have a coating that slowly releases a drug that helps prevent the artery from re-narrowing over time.

In general, drug-eluting stents are preferred over bare metal stents. However, drug-eluting stents require 6-12 months of treatment with anti-platelet drugs, which increases a patient’s risk of bleeding and possibly other side effects.

Although millions of people are implanted with drug-eluting stents every year, the safety of anti-platelet therapy beyond 12 months is poorly understood. So researchers decided to investigate the risk of side effects at 12 months and 30 months.

Surprisingly, researchers found about 2% of patients died after taking anti-platelet drugs for 30 months, compared to 1.5% of patients on a placebo. Prolonged use of anti-platelet drugs also significantly increased the risk of bleeding. About 1 in 1,000 of those bleeds were fatal.

Conclusions were based on data from the Dual Anti-Platelet Therapy (DAPT) study, which enrolled 10,000 patients. The study was published in November 2014 by the New England Journal of Medicine.

In response, the FDA published a Safety Communication to announce that they will review the results, but they have made no conclusions and are not recommending any changes to the way anti-platelet drugs are prescribed.

According to the FDA:

“The higher rate of death was largely explained by an increase in deaths from non-cardiovascular causes, primarily cancer and trauma deaths. The increased risk of death with longer treatment was seen in the patients given clopidogrel, but not those given prasugrel.”

Free Case Review

Verified 100% Secure Site

To contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 879-3040.

*
*
*